<DOC>
	<DOCNO>NCT02248142</DOCNO>
	<brief_summary>Study evaluate treatment effect pramipexole RLS severity measure IRLS , CGI-I RLS-6 evaluate time need reach maintenance dose Pramipexole ( PPX )</brief_summary>
	<brief_title>Observational Study SifrolÂ® Patients With Primary Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Patients suffer primary RLS plan initiate treatment pramipexole part routine care could include study Patients pretreated dopaminergic agent ( de novo patient ) patient pretreated dopaminergic medication Male female patient age Treating physician ask consider regulation describe Summary Product Characteristics ( SPC ) treatment pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>